WO2021098755A1 - 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用 - Google Patents

乳双歧杆菌bl-99在抑制肠道炎症方面的新应用 Download PDF

Info

Publication number
WO2021098755A1
WO2021098755A1 PCT/CN2020/129990 CN2020129990W WO2021098755A1 WO 2021098755 A1 WO2021098755 A1 WO 2021098755A1 CN 2020129990 W CN2020129990 W CN 2020129990W WO 2021098755 A1 WO2021098755 A1 WO 2021098755A1
Authority
WO
WIPO (PCT)
Prior art keywords
bifidobacterium lactis
composition
mice
group
cfu
Prior art date
Application number
PCT/CN2020/129990
Other languages
English (en)
French (fr)
Inventor
赵雯
刘锦浲
刘伟贤
洪维鍊
庞飞
尹小静
张海斌
Original Assignee
内蒙古伊利实业集团股份有限公司
内蒙古乳业技术研究院有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 内蒙古伊利实业集团股份有限公司, 内蒙古乳业技术研究院有限责任公司 filed Critical 内蒙古伊利实业集团股份有限公司
Priority to EP20889353.7A priority Critical patent/EP4070805A4/en
Priority to JP2022529588A priority patent/JP7492584B2/ja
Priority to US17/778,587 priority patent/US20220401499A1/en
Publication of WO2021098755A1 publication Critical patent/WO2021098755A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/18—Milk in dried and compressed or semi-solid form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Definitions

  • the present invention relates to the field of microbial technology, in particular to a new application of Bifidobacterium lactis BL-99 (preservation number CGMCC No. 15650) in inhibiting intestinal inflammation.
  • enteritis With the influence of environmental factors, diet, and living habits on the microenvironment of the intestinal flora, the incidence of enteritis has also increased year by year, and enteritis has become one of the important diseases affecting human health in the world. At present, a large number of studies have shown that oxidative damage of intestinal cells, mucosal damage, intestinal epithelial cells, release of toxins and other harmful substances, resulting in intestinal epithelial cell damage and death, enhanced intestinal epithelial permeability, pathogenic bacteria, etc.
  • enteritis can be divided into modern medical treatment and traditional Chinese medicine treatment.
  • adjusting the balance of intestinal flora by supplementing probiotics in vitro has also become an important method to reduce intestinal inflammation.
  • probiotics can antagonize pathogenic bacteria, are safe, controllable, effective, and have low side effects. They are an ideal method for the treatment of enteritis.
  • the mechanism of probiotics in the treatment of enteritis has not been thoroughly studied.
  • probiotics can inhibit the colonization of pathogenic bacteria by competing for nutrients and co-receptors, or directly inhibit pathogenic bacteria by producing bacteriocins, or by producing Antitoxin proteases, etc. isolate pathogenic bacteria and their toxins.
  • Probiotics maintain the normal intestinal flora, strengthen the mucosal barrier, inhibit the exposure of inflammatory signals, the immune system adjusts the imbalanced immune response, and inhibits host mucosal damage.
  • WGO World Gastrointestinal Organization
  • An object of the present invention is to provide a new use of Bifidobacterium lactis BL-99.
  • the present invention provides a kind of Bifidobacterium lactis, which is named BL-99 in the present invention.
  • This strain has been deposited on April 26, 2018 in the CGMCC (Address: No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences), CGMCC, China Common Microbial Species Collection Management Center. Classification and name: Bifidobacterium lactis Bifidobacterium lactis; the deposit number is CGMCC No. 15650.
  • the Bifidobacterium lactis provided by the present invention has gastric acid resistance and intestinal juice resistance.
  • the survival rate of live bacteria is more than 62% when treated in gastric acid with pH 2.5 for 30 minutes, and the survival rate of live bacteria is 61% after treatment for 2 hours. Above: The survival rate of viable bacteria is more than 70% when treated in the small intestine juice at pH 6.8 for 2 hours.
  • Bifidobacterium lactis BL-99 ie Bifidobacterium lactis with the deposit number of CGMCC No. 15650 strain has the effect of inhibiting intestinal inflammation, and can reduce the inflammatory factor IL-6 and/or TNF- ⁇ , promotes the anti-inflammatory factor IL-10, reduces colitis tissue damage.
  • the present invention provides the application of Bifidobacterium lactis in the preparation of a composition for inhibiting intestinal inflammation, and the deposit number of the Bifidobacterium lactis is CGMCC No. 15650.
  • the present invention provides a Bifidobacterium lactis for inhibiting intestinal inflammation, and the deposit number of the Bifidobacterium lactis is CGMCC No. 15650.
  • the Bifidobacterium lactis may exist in the form of a composition including it.
  • the present invention also provides a method for inhibiting intestinal inflammation, which comprises administering to a subject an effective amount of Bifidobacterium lactis (Bifidobacterium lactis), the deposit number of the Bifidobacterium lactis is CGMCC No.15650.
  • Bifidobacterium lactis may be administered to the subject in the form of a composition including the same.
  • the Bifidobacterium lactis is used to prepare the composition in the form of a solid or liquid bacterial preparation.
  • the Bifidobacterium lactis is used to prepare the composition in the form of live bacteria and/or dead bacteria.
  • the composition may include a food composition, a feed composition or a pharmaceutical composition.
  • the composition can be used in animals or humans.
  • the composition may also include conventional material components in the field.
  • auxiliary materials may be included, and the auxiliary materials may be excipients, diluents, fillers, absorption enhancers, and the like.
  • the Bifidobacterium lactis of the present invention can be produced according to the food containing Bifidobacterium lactis in the prior art, and the composition can adopt different forms according to the needs of the recipient. For example, powder, lozenge, granulation, microcapsule, liquid preparation and so on.
  • the composition is used to reduce the inflammatory factors IL-6 and/or TNF- ⁇ .
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 6 CFU to 3.88 ⁇ 10 13 CFU/day, or 0.01 ⁇ g to 100 mg/day based on the weight of the bacteria.
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 8 CFU to 3.88 ⁇ 10 12 CFU/day, or 0.1 ⁇ g to 10 mg/day based on the weight of the bacteria.
  • the composition is used to promote the anti-inflammatory factor IL-10.
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 6 CFU to 3.88 ⁇ 10 13 CFU/day, or 0.01 ⁇ g to 100 mg/day based on the weight of the bacteria.
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 8 CFU to 3.88 ⁇ 10 12 CFU/day, or 0.1 ⁇ g to 10 mg/day based on the weight of the bacteria.
  • the composition is used to reduce colitis tissue damage.
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 6 CFU to 3.88 ⁇ 10 13 CFU/day, or 0.01 ⁇ g to 100 mg/day based on the weight of the bacteria.
  • the application amount of the Bifidobacterium lactis is 3.88 ⁇ 10 8 CFU to 3.88 ⁇ 10 12 CFU/day, or 0.1 ⁇ g to 10 mg/day based on the weight of the bacteria.
  • the composition may also include biocompatible excipients to prepare solutions, suspensions, emulsions, powders, lozenges, The dosage forms of pills, syrups, lozenges, tablets, chewing gums, or capsules for general application or medical use.
  • the composition is a food composition
  • the food may be fermented dairy products (such as fermented milk, flavored fermented milk, fermented milk beverages, etc.), cheese, milk-containing beverages, solid beverages, etc. Or milk powder and so on.
  • the composition is a feed composition.
  • Other components in the feed composition can be selected with reference to conventional techniques in the field of probiotic feeds.
  • the composition is a pharmaceutical composition.
  • Other components in the pharmaceutical composition can be selected with reference to conventional techniques in the field of probiotic drugs.
  • the present invention provides a new use of Bifidobacterium lactis BL-99, which has a significant inhibitory effect on intestinal inflammation, can reduce inflammatory factors IL-6 and/or TNF- ⁇ , and promote anti-inflammatory factor IL -10, reduce the damage of colitis tissue, can be used to prepare foods, medicines and feeds with the effect of inhibiting intestinal inflammation, and has a wide range of application prospects.
  • Figure 1 shows the effect of Bifidobacterium lactis BL-99 on IL-6 in mouse colon.
  • Figure 2 shows the effect of Bifidobacterium lactis BL-99 on IL-10 in mouse colon.
  • Figure 3 shows the effect of Bifidobacterium lactis BL-99 on mouse colon TNF- ⁇ .
  • Figure 4 shows the pathological section results of the effect of Bifidobacterium lactis BL-99 on mice.
  • Figure 5 shows the score results of the histological damage of Bifidobacterium lactis BL-99 in mice.
  • the Bifidobacterium lactis BL-99 of the present invention is the Bifidobacterium lactis BL-99 of the present invention.
  • CGMCC General Microbiology Center
  • Bifidobacterium lactis (Bifidobacterium lactis).
  • Example 1 Bifidobacterium lactis BL-99 and its performance measurement
  • the Bifidobacterium lactis BL-99 of the present invention comes from Shanghai Jiaotong University Onlly Co., Ltd., and is isolated from the intestines of infants. This strain has been deposited on April 26, 2018 in the CGMCC (Address: No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences), CGMCC, China Common Microbial Species Collection Management Center. Classification and name: Bifidobacterium lactis Bifidobacterium lactis; the deposit number is CGMCC No. 15650.
  • Bifidobacterium is a genus of bacteria that are generally not acid-resistant.
  • the artificial gastric juice and intestinal juice tolerance of the Bifidobacterium lactis BL-99 of the present invention were tested, and the Bifidobacterium lactis, which is recognized in the field as having excellent acid resistance and can survive through the gastrointestinal tract, As a comparison.
  • Test method After culturing the Bifidobacterium lactis BL-99 strain in MRS liquid medium at 37°C for 16 hours, centrifuge at 4°C and 2500 rpm for 10 minutes to collect the bacteria.
  • the tested strains were cultured in artificial gastric juice and artificial small intestinal juice, and then treated at 37°C for 0, 30min, and 2h, and then counted and analyzed for viable bacteria.
  • the test results of the survival rate of strains in artificial gastric acid (pH 2.5) are shown in Table 1.
  • the survival rate of live bacteria when BB-12 is treated in artificial gastric acid (pH 2.5) for 30 minutes is 7.04%, and the survival rate of live bacteria is treated for 2 hours. Only 1.64%; while the Bifidobacterium lactis BL-99 of the present invention is treated in artificial gastric acid (pH 2.5) for 30 minutes, the survival rate of live bacteria is 62.60%, and the survival rate of live bacteria is 61.83% after treatment for 2 hours. It shows that the Bifidobacterium lactis BL-99 of the present invention has excellent gastric acid resistance, and can more smoothly pass through the stomach to the intestine to exert a probiotic effect.
  • the Bifidobacterium lactis BL-99 of the present invention was inoculated into the BBL liquid medium and cultured anaerobic at 36 ⁇ 1°C for 48 ⁇ 2 hours.
  • the number of viable Bifidobacterium lactis BL-99 in the culture solution was 3.7 ⁇ 10 8 cfu/mL
  • the stock solution of the culture and the 5-fold concentrated solution were orally administered to the test mice at 20.0mL/kg BW for 3 consecutive days and observation for 7 days.
  • the experiment set up a medium stock solution and a 5-fold concentrated solution control group.
  • Bifidobacterium lactis BL-99 The method of SN/T 1944-2007 "Determination of Bacterial Resistance in Animals and Their Products" was used to evaluate the antibiotic sensitivity of Bifidobacterium lactis BL-99.
  • the evaluation results show that Bifidobacterium lactis BL-99 is sensitive to Ampicillin, Penicillin G, Erythromycin, Chloramphenicol, Clindamycin, Vancomycin, and Tetracycline. It meets the requirements of the European Food Safety Authority (European Food Safety Authority) for the evaluation of drug resistance of edible bacteria.
  • Bifidobacterium lactis BL-99 does not contain foreign antibiotic resistance genes and is safe to eat.
  • Example 2 Bifidobacterium lactis BL-99 inhibitory effect of intestinal inflammation
  • Healthy BABL/c male mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. Raised in the animal room of the Chinese Center for Disease Control and Prevention, maintained at room temperature (25 ⁇ 2°C), relative humidity (55 ⁇ 2)%, 12h/12h alternate day and night light, and free eating and drinking.
  • mice 112 healthy BABL/c male mice, 6-8 weeks old, weighing 20-22g, were divided into 8 groups using random numbers according to their body weights, each with 14 mice. Each group was reared in two cages, each with 7 animals, using picric acid numbers, and was fed adaptively with ordinary feed for 5 days. See Table 3 for specific grouping and sample size. Intervene mice by gavage, the gavage volume is 0.4ml/20g. The intervention period is 14 days.
  • the dead bacteria sample is the BL-99 inactivated sample, that is, after the BL-99 sample is prepared according to the requirements, it is inactivated by heating in a water bath at 100°C for 20 minutes, PBS is constant volume, and refrigerated for later use.
  • mice except for the control group, the remaining 7 groups need to establish DSS-induced experimental colitis models.
  • a 5.0% DSS aqueous solution was prepared instead of drinking water, and they were free to drink for 7 days.
  • the normal group drank distilled water. Observe the changes in the physical signs of the mice daily.
  • mice were anesthetized by intraperitoneal injection of sodium pentobarbital, blood was taken from the abdominal aorta, and the serum was separated by centrifugation. Separate the mouse colon, wash it with PBS several times, measure the length, cut 2/3, store in a centrifuge tube, and store at -80°C. 1/3 is stored in 10% formalin solution and fixed for later use.
  • the Fedorak histological score standard was used for histological scoring.
  • the histological injury scoring standard is shown in Table 4.
  • cytokines IL-6, IL-10 and TNF- ⁇ in mouse colon were determined according to the instructions of the ELISA kit.
  • the experimental data is expressed as Mean ⁇ S.E.M.
  • the data is calculated using PRISM version 5.0 (GraphPad, San Diego, CA, USA). Differences between groups are counted using one-way ANOVA followed by Tukery’s multiple comparison test. There is a significant statistical difference when P ⁇ 0.05.
  • mice The weight of the mice at 0 days, 7 days, and 14 days was counted, and the results are shown in Table 5.
  • the body weight of the mice in the model group and each intervention group decreased significantly, indicating that despite the sample intervention, the weight of the mice still decreased under the premise that DSS caused intestinal damage.
  • the weight of mice in each intervention group was significantly lower than that of the control group (p ⁇ 0.05), and there was no significant difference compared with the model group (p>0.05). It shows that the sample has limited intervention effect on the body weight of the mice modeled by DSS.
  • mice in each group have smooth coat color, mentally active, flexible response, normal eating, no diarrhea and bloody stools, and stools are spherical or bar-shaped; after 7 days of modeling, the mice in the model group and the intervention group have passed 5.0% The DSS induced the formation of an experimental colitis model. Observe the physical signs of the mice in each experimental group during the modeling period, and the results are shown in Table 6.
  • mice The observation results of intestinal inflammation symptoms in mice showed that the intervention effects of each sample on DSS model mice were shown in the following aspects: (1) The number of bloody stools in mice decreased after the experiment; (2) The time and time when mice appeared bloody stools The model group was delayed by 1 to 2 days. Therefore, in this model, 5% DSS was used instead of drinking water, possibly because the mice's intake and tolerance to DSS were different, and the death of mice did not change with the dose.
  • the weight of the spleen of each group of mice is shown in Table 7. It can be seen that compared with the control group, the spleen index of the model group is significantly higher than that of the control group (p ⁇ 0.05), indicating that 5% DSS can stimulate the proliferation of mouse spleen lymphocytes and macrophages, and stimulate the body to exert cellular immunity and humoral The role of immunity.
  • the BL-99 middle-dose group and the dead bacteria low-dose group have a tendency to decrease in the spleen index. It can be speculated that the inactivated bacteria of the middle-dose group BL-99 and the low-dose group may have the function of reducing the body's inflammatory response.
  • mice colon length are shown in Table 8. After modeling, the colon length of the model group was significantly lower than that of the control group (p ⁇ 0.05); after sample intervention, the colon length of each group was not significantly different from that of the model group. (p>0.05), indicating that the main effect on the length of the mouse colon in this experiment is 5% DSS, and short-term intervention of the sample has no significant effect on the length of the mouse colon.
  • IL-6 in the colon The changes of IL-6 in the colon are shown in Figure 1. Compared with the control group, the IL-6 in the colon of mice in the model group was significantly higher than that in the control group (p ⁇ 0.05), indicating that the intervention of DSS in mice can cause intestinal inflammation in mice. Increase, manifested as an increase in the inflammatory factor IL-6. Compared with the model group, IL-6 in the colon of mice in the BL-99 medium-dose group and the dead bacteria low-dose group was significantly lower than that of the model group (p ⁇ 0.05); Dead bacteria can reduce the intestinal inflammation in mice.
  • the pathological section results are shown in Figure 4. Histological observation of the mice in the control group can see intact colonic epithelial cells, as well as clear crypt structures and goblet cells. Histological observation of colitis mice in the model group induced by DSS showed that intact colonic epithelial cells could not be seen. At the same time, incomplete crypts and goblet cell damage appeared. The damaged area was more than 50%, and some mice were cryptic. The nest disappeared completely, and the cup shape was completely destroyed. In addition, mouse inflammatory cell infiltration can also be observed, such as neutrophils and lymphocytes. After the intervention of BL-99, the mice were modeled by DSS. Inflammatory cell infiltration occurred, a small number of crypts disappeared, and goblet cells were destroyed.
  • the middle-dose group had more severe inflammation, and the lesion range was 50-75%.
  • the range of lesions in the low-dose and high-dose groups is relatively limited, most of which are in the range of 0-25%.
  • the DSS model showed inflammatory cell infiltration, a wide area of crypt disappearance, goblet cells were destroyed, and the lesion area was more serious, most of which were within 50%.
  • the histological damage score results are shown in Figure 5. Compared with the model group, the colonic histological damage scores of each group have a downward trend. Among them, the BL-99 low and high dose group and the dead bacteria low, medium and high dose group histology The injury scores were significantly lower than those of the model group (p ⁇ 0.05), indicating that the probiotics of the above groups can reduce the inflammation symptoms of the mice's colon.
  • DSS-induced colitis is the most common method for experimental animal colitis models. Usually, mice can drink freely for about 7 days to form an experimental colitis model. In this experiment, 5% DSS was used as the modeling concentration. The model group was dead, and the mice began to have blood in the stool on the third day. With time, the blood in the stool became worse and the number of blood in the stool increased, indicating that the model was established with good stability.
  • the bloody stools of the mice in each dose group of BL-99 were later than that of the model group.
  • the number of bloody stools in the mice was less than that of the model group, and the symptoms were lighter, which directly indicated the anti-inflammatory effect of probiotics.
  • the bloody stool time of the mice in the dead bacteria intervention group was the same as that of the model group, and bloody stool appeared more frequently. This is because the probiotics were inactivated, their regulatory effect on the intestinal tract was reduced, resulting in a higher incidence of intestinal inflammation.
  • IL-6 is a multifunctional key cytokine that can regulate the expression of other cytokines.
  • IL-6 is a pro-inflammatory factor, and its expression level is closely related to the degree of inflammation in colon studies. Mice lacking IL-10 show severe intestines. Tract inflammation, and IL-10 has a good therapeutic effect in animal colitis models.
  • TNF- ⁇ is a cytokine involved in systemic inflammation. In this study, IL-6 in the colon of mice in the model group was significantly increased, while the IL-6 in the colon of mice in the BL-99 medium, high-dose and dead bacteria low-dose groups was lower than that of the model group.
  • mice colon tissue damage scores are significantly different from the model group.
  • the specific manifestations are that the degree of inflammatory cell infiltration is lower, the depth of the lesion is mainly in the submucosa, and the basal crypts are less damaged.
  • the scope of the slice lesions is also small, which intuitively shows that BL-99 live and dead bacteria can reduce the degree of inflammation in the colon of DSS model mice.
  • Bifidobacterium lactis BL-99 can significantly inhibit the inflammatory factors IL-6 and TNF- ⁇ , enhance the anti-inflammatory factor IL-10, and restore the effect of colon tissue loss. It can be used in foods, such as fermented milk and cheese , Milk-containing beverages, milk powder or any other food containing the strain and its derivatives.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dairy Products (AREA)

Abstract

乳双歧杆菌BL-99及其在抑制肠道炎症方面的应用。乳双歧杆菌(Bifidobacterium lactis)BL-99，其保藏编号为CGMCC No.15650。该菌株具有抑制肠道炎症的功效，能够降低炎症因子IL-6和/或TNF-α，促进抑炎因子IL-10，降低结肠炎组织损伤。

Description

乳双歧杆菌BL-99在抑制肠道炎症方面的新应用 技术领域
本发明涉及微生物技术领域，尤其是涉及一种乳双歧杆菌(Bifidobacterium lactis)BL-99(保藏编号CGMCC No.15650)在抑制肠道炎症方面的新应用。
背景技术
随着环境因素、饮食、生活习惯等对肠道菌群微环境的影响，肠炎的发病率也逐年上升，肠炎已经成为影响全球人类健康的重要疾病之一。目前已有大量研究表明，肠道细胞的氧化损伤，粘膜受损、感染肠道上皮细胞、释放毒素等有害物质、致使肠道上皮细胞损伤死亡，肠道上皮通透性增强、致病菌等透过损伤的肠道粘膜屏障、进入组织内部，引发系列的免疫应答，导致巨噬细胞产生大量的细胞因子，过度刺激T细胞，产生促炎因子，使上皮细胞发生炎症反应。
肠炎传统的治疗方法可分为现代医学治疗和中药治疗方法。随着科学技术的发展，通过体外补充益生菌的方法调节肠道菌群平衡也成为了降低肠道炎症的重要方法。益生菌作为肠道内源性和免疫性防御屏障，能够拮抗致病菌，具有安全、可控、有效、副作用小的特点，是治疗肠炎的理想方法。益生菌治疗肠炎的机制目前尚未研究透彻，目前普遍归功于益生菌可通过竞争营养性物质、竞争共同受体抑制致病菌定殖、或者通过产生细菌素直接抑制致病菌，亦或通过产生抗毒素蛋白酶等隔绝致病菌及其毒素。益生菌通过维持肠道正常菌群，加强粘膜屏障作用，抑制炎症信号的暴露免疫***对失衡的免疫应答进行调整，抑制宿主粘膜损伤。此外，世界肠胃组织(WGO)全球指南中已指出将益生菌制剂作为炎症性肠病药物。
发明内容
本发明的一个目的在于提供一种乳双歧杆菌BL-99的新用途。
本发明提供了一种乳双歧杆菌(Bifidobacterium lactis)，本发明中命名为BL-99。该菌株已于2018年04月26日保藏于中国普通微生物菌种保藏管理中心CGMCC(地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所)，分类命名：乳双歧杆菌(Bifidobacterium lactis)；保藏编号为CGMCC No.15650。本发明提供的乳双歧杆菌(Bifidobacterium lactis)，其具有耐胃酸和耐肠液性能，在pH2.5的胃酸液中处 理30min时活菌存活率62％以上，处理2小时活菌存活率61％以上；在pH6.8的小肠液中处理2小时活菌存活率70％以上。
本发明的研究发现，乳双歧杆菌BL-99(即保藏编号为CGMCC No.15650的乳双歧杆菌)菌株单菌即具有抑制肠道炎症的功效，能够降低炎症因子IL-6和/或TNF-α，促进抑炎因子IL-10，降低结肠炎组织损伤。
从而，本发明提供了乳双歧杆菌(Bifidobacterium lactis)在制备用于抑制肠道炎症的组合物中的应用，所述乳双歧杆菌的保藏编号为CGMCC No.15650。
换而言之，本发明提供了一种用于抑制肠道炎症的乳双歧杆菌(Bifidobacterium lactis)，所述乳双歧杆菌的保藏编号为CGMCC No.15650。所述乳双歧杆菌可以包括其的组合物的形式存在。
从另一角度而言，本发明还提供了一种抑制肠道炎症的方法，其包括给予受试者有效量的乳双歧杆菌(Bifidobacterium lactis)，所述乳双歧杆菌的保藏编号为CGMCC No.15650。所述乳双歧杆菌可以包括其的组合物的形式施予受试者。
根据本发明的具体实施方案，所述乳双歧杆菌以固态或液态菌制剂的形式用于制备所述组合物。
根据本发明的具体实施方案，所述乳双歧杆菌以活菌和/或死菌的形式用于制备所述组合物。
根据本发明的具体实施方案，所述组合物可以包括食品组合物、饲料组合物或药品组合物。
根据本发明的具体实施方案，所述组合物可使用于动物或是人类。所述组合物还可包括所属领域中的常规用料组分。例如，对于药物组合物，可包括适量的辅料，所述辅料可以为赋型剂、稀释剂、填充剂、吸收促进剂等。对于食品组合物，本发明的乳双歧杆菌可以按照现有技术中含乳双歧杆菌的食品进行生产，所述组合物可根据受施予者的需要，而采用不同形态。例如粉剂、锭剂、造粒、微胶囊、液体制剂等。
根据本发明的具体实施方案，所述组合物是用于降低炎症因子IL-6和/或TNF-α。具体应用时，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天，或者以菌体的重量计为0.01μg～100mg/天。优选地，所述乳双歧杆菌的应用量为3.88×10 8CFU～3.88×10 12CFU/天，或者以菌体的重量计为0.1μg～10mg/天。
根据本发明的具体实施方案，所述组合物是用于促进抑炎因子IL-10。具体应用时，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天，或者以菌体的重量 计为0.01μg～100mg/天。优选地，所述乳双歧杆菌的应用量为3.88×10 8CFU～3.88×10 12CFU/天，或者以菌体的重量计为0.1μg～10mg/天。
根据本发明的具体实施方案，所述组合物是用于降低结肠炎组织损伤。具体应用时，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天，或者以菌体的重量计为0.01μg～100mg/天。优选地，所述乳双歧杆菌的应用量为3.88×10 8CFU～3.88×10 12CFU/天，或者以菌体的重量计为0.1μg～10mg/天。
在本发明的一具体实施方案中，所述组合物除乳双歧杆菌BL-99外，也可以包括生物可兼容的赋形剂，以制备成溶液、悬浮液、乳剂、粉末、锭剂、丸剂、糖浆、***锭、片剂、口嚼胶、或胶囊的剂型，供一般应用或医药使用。
在本发明的一具体实施方案中，所述组合物为食品组合物，所述食品可以为发酵乳制品(例如发酵乳、风味发酵乳、发酵乳饮料等)、乳酪、含乳饮料、固体饮料或乳粉等。
在本发明的另一具体实施方案中，所述组合物为饲料组合物。所述饲料组合物中的其他组分可以参照益生菌饲料领域的常规技术进行选择。
在本发明的另一具体实施方案中，所述组合物为药物组合物。所述药物组合物中的其他组分可以参照益生菌药物领域的常规技术进行选择。
综上所述，本发明提供了乳双歧杆菌BL-99的新用途，该菌具有显著抑制肠道炎症的功效，能够降低炎症因子IL-6和/或TNF-α，促进抑炎因子IL-10，降低结肠炎组织损伤，可以用于制备具有抑制肠道炎症功效的食品、药物及饲料等，具有广泛的应用前景。
附图说明
图1显示乳双歧杆菌BL-99对小鼠结肠IL-6的影响。
图2显示乳双歧杆菌BL-99对小鼠结肠IL-10的影响。
图3显示乳双歧杆菌BL-99对小鼠结肠TNF-α的影响。
图4显示乳双歧杆菌BL-99对小鼠影响的病理学切片结果。
图5显示乳双歧杆菌BL-99对小鼠组织学损伤评分结果。
专利程序的微生物保存：
本发明的乳双歧杆菌BL-99：
保藏日期：2018年04月26日；
保藏单位：中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)；
保藏单位地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所
保藏编号：CGMCC No.15650；
分类命名：乳双歧杆菌(Bifidobacterium lactis)。
具体实施方式
为了对本发明的技术特征、目的和有益效果有更加清楚的理解，现结合具体实施例及对本发明的技术方案进行以下详细说明，应理解这些实例仅用于说明本发明而不用于限制本发明的范围。实施例中，各原始试剂材料均可商购获得，未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件，或按照仪器制造商所建议的条件。
实施例1：乳双歧杆菌BL-99及其性能测定
本发明的乳双歧杆菌BL-99，来自上海交大昂立股份有限公司，是自婴儿肠道中分离得到的。该菌株已于2018年04月26日保藏于中国普通微生物菌种保藏管理中心CGMCC(地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所)，分类命名：乳双歧杆菌(Bifidobacterium lactis)；保藏编号为CGMCC No.15650。
1.乳双歧杆菌BL-99的分类学特征
理化试验结果：
Figure PCTCN2020129990-appb-000001
16S rRNA基因序列测序结果(SEQ ID No.1)：
Figure PCTCN2020129990-appb-000002
2.乳双歧杆菌BL-99的人工胃液、肠液耐受性
双歧杆菌为通常不抗酸的菌属。本实施例中，测试了本发明的乳双歧杆菌BL-99的人工胃液、肠液耐受性，同时以目前领域中公认耐酸性能极好、可以通过胃肠道存活的乳双歧杆菌
Figure PCTCN2020129990-appb-000003
作为对比。
测试方法：将乳双歧杆菌BL-99菌株于MRS液体培养基中37℃培养16小时后，于4℃、2500rpm下离心10min，收集菌体。
将待测菌株分别在人工胃液、人工小肠液中培养，37℃处理0、30min、2h后进行活菌计数分析，以存活率评价菌株的耐酸及耐肠液性能。存活率＝(处理后的活菌数/0时刻活菌数)×100％。
菌株在人工胃酸(pH2.5)中的存活率检测结果如表1所示，BB-12在人工胃酸(pH2.5)中处理30min时活菌存活率7.04％，处理2小时活菌存活率仅1.64％；而本发明的乳双歧杆菌BL-99在人工胃酸(pH2.5)中处理30min时活菌存活率62.60％，处理2小时活菌存活率61.83％。表明本发明的乳双歧杆菌BL-99具有优异的耐胃酸能力，能较为顺利地通过胃到达肠道发挥益生作用。
表1菌株在人工胃酸(pH2.5)中的存活率
Figure PCTCN2020129990-appb-000004
菌株在人工小肠液(pH6.8)中的存活率检测结果参见表2。数据显示，BB-12在人工小肠液(pH6.8)中处理2小时活菌存活率仅28.95％；而本发明的乳双歧杆菌BL-99在人工胃酸(pH2.5)中处理2小时活菌存活率70.23％。表明本发明的乳双歧杆菌BL-99具有优异的耐肠液能力，可以在肠道内存活并定殖。
表2菌株在人工小肠液(pH6.8)中的存活率
Figure PCTCN2020129990-appb-000005
3.乳双歧杆菌BL-99的的毒力实验及安全性检测
将本发明的乳双歧杆菌BL-99接种于BBL液体培养基中，36±1℃厌氧培养48±2小时，计数培养液中乳双歧杆菌BL-99活菌数为3.7×10 8cfu/mL，将培养物的原液和5倍浓缩液，经口以20.0mL/kg BW给受试小鼠连续灌胃3天，观察7天。试验设培养基原液和5倍浓缩液对照组。试验结果表明：乳双歧杆菌BL-99的BBL培养物原液和5倍浓缩液组与各自对照组相比，对小鼠体重增长的影响无统计学意义(p＞0.05)，同时未观察到受试小鼠有毒性反应或死亡。
采用SN/T 1944-2007《动物及其制品中细菌耐药性的测定》方法，评估乳双歧杆菌BL-99的抗生素敏感性能。评价结果显示，乳双歧杆菌BL-99对氨苄西林Ampicillin、青霉素G PenicillinG、红霉素Erythromycin、氯霉素Chloramphenicol、克林霉素Clindamycin、万古霉素Vancomycin和四环素Tetracycline等敏感。符合欧洲食品安全委员会(European Food Safety Authority)对食用细菌耐药性评价规范中的要求。乳双歧杆菌BL-99不含外源抗生素耐药基因，食用安全。
实施例2：乳双歧杆菌BL-99抑制肠道炎症功效实验
1.实验材料
健康BABL/c雄性小鼠，购自北京华阜康生物科技有限责任公司。饲养于中国疾病预防控制中心动物房，维持室温(25±2℃)，相对湿度(55±2)％，12h/12h昼夜交替光照，自由进食和饮水。
2.实验方法
2.1动物分组及处理
健康BABL/c雄性小鼠112只，鼠龄6～8周，体重20～22g，依据体重，利用随机数字，分为8组，每组14只。每组分两笼饲养，每笼7只，使用苦味酸编号，普通饲料适应性喂养5天。具体分组及样品量见表3。以灌胃方式干预小鼠，灌胃体积为0.4ml/20g。干预周期为14天。
表3实验分组
Figure PCTCN2020129990-appb-000006
死菌样品为BL-99灭活样品，即将BL-99样品依照需求配制完成后，100℃水浴 加热灭活20min，PBS定容，冷藏备用。
8组小鼠，除对照组外，其余7组需要进行DSS诱导的实验性结肠炎模型的建立。在实验过程第8天，配制5.0％的DSS水溶液替代饮水，自由饮用7天，正常组饮用蒸馏水。每日观察小鼠体征变化。
2.2结肠长度及重量测定
干预结束后，小鼠戊巴比妥钠腹腔注射麻醉，腹主动脉取血，离心分离血清。分离小鼠结肠，以PBS冲洗多次后，测量长度，剪切2/3存于离心管中，-80℃保存。1/3储存于10％***溶液中固定备用。
2.3结肠组织病理学观察及评分
结肠放入***溶液固定后，依次经过脱水、浸蜡、包埋、切片、捞片和烤片，脱蜡复水，HE染色，最后显微镜观察组织形态学。
采用Fedorak组织学积分标准进行组织学评分。组织学伤损评分标准如表4所示。
表4组织学损伤评分标准
评分 炎症 病变深度 隐窝破坏 病变范围
0 无 无 无 /
1 轻度 粘膜下层 基底1/3隐窝破坏 1％-25％
2 中毒 肌层 基底2/3隐窝，破坏 26％-50％
3 / 浆膜层 仅有完整表面上皮 51％-75％
4 / / 全部隐窝和上皮被破坏 76％-100％
2.4血清中细胞因子测定
按照ELISA试剂盒说明书对小鼠结肠中细胞因子IL-6、IL-10、TNF-α含量进行测定。
2.5统计分析方法
实验数据表示为Mean±S.E.M.数据采用PRISM version 5.0(GraphPad,San Diego,CA,USA)进行统计。组间差异采用one-way ANOVA跟随Tukery’s multiple comparison test的方法进行统计。P<0.05时具有显著的统计学差异。
3.实验结果与分析
3.1小鼠体重变化
对小鼠0天、7天、14天体重进行统计，结果如表5。
表5小鼠体重变化
分组 0天 7天 14天
对照组 20.92±0.56 22.25±0.88 22.68±1.02
模型组 21.36±0.99 23.18±1.21 19.19±2.28*
低剂量组 21.39±0.98 22.88±1.55 19.89±2.42*
中剂量组 21.22±0.64 23.06±1.38 19.37±1.71*
高剂量组 21.01±0.79 22.17±0.93 19.13±1.78*
死菌低剂量组 20.76±0.96 22.66±1.34 20.43±2.59*
死菌中剂量组 21.39±1.10 22.15±1.61 19.12±2.70*
死菌高剂量组 21.04±1.39 23.16±1.85 19.51±2.35*
注：*与对照组比较，差异具有显著性。
0天时，小鼠体重组间比较无显著性差异(p＜0.05)；表明实验开始时小鼠状态一致，可排除小鼠体重不同造成的实验差异。给予样品7天后，各组小鼠体重均增加，组间比较无显著性差异(p＜0.05)，表明短时间样品干预对小鼠的体重增长无影响。5％DSS代替饮水7天后，模型组小鼠体重均显著降低(p＜0.05)，而对照组体重无显著性变化(p＞0.05)，同时参考小鼠状态观察结果，表示模型组造模成功。造模后，模型组和各干预组小鼠体重均显著降低，表明虽然经样品干预，但在DSS造成肠道损伤的前提下，小鼠体重依然减少。造模后，各干预组小鼠体重显著低于对照组(p＜0.05)，与模型组比较无显著性差异(p＞0.05)。表明样品对于经DSS造模小鼠体重的干预作用有限。
3.2 DSS诱导小鼠结肠炎症特征观察
0-7天，各组小鼠毛色光滑，精神活跃，反应灵活，正常进食，无腹泻及血便，大便呈球形或条形；经过7天造模，模型组与干预组小鼠均经过5.0％的DSS诱导形成了实验性结肠炎模型。分别观察个实验组小鼠在造模期的体征变化，结果如表6。
表6小鼠体征观察
Figure PCTCN2020129990-appb-000007
Figure PCTCN2020129990-appb-000008
小鼠肠道炎症症状观察结果表明，各样品对DSS造模小鼠的干预作用表现在以下几个方面：(1)实验结束小鼠血便只数减少；(2)小鼠出现血便的时间与模型组比较推迟1～2天。因此次造模以5％DSS代替饮水，可能因为小鼠对DSS的摄入量与耐受程度不同，小鼠的死亡未随着剂量而变化。
3.3各组小鼠脾脏重量
各组小鼠脾脏重量见表7。可知，与对照组比较，模型组小鼠脾脏指数均显著高于对照组(p＜0.05)，表明5％DSS可刺激小鼠脾脏淋巴细胞和巨噬细胞的增殖，刺激机体发挥细胞免疫和体液免疫的作用。BL-99中剂量组与死菌低剂量组在脾脏指数上具有降低的趋势，可以得出推测，中剂量组BL-99与低剂量组灭活菌可能具有减少机体炎性反应的功能。
表7小鼠脾脏重量/指数
组别 脾脏重量(g) 脾脏指数
对照组 0.081±0.011 0.36±0.05
模型组 0.085±0.021 0.44±0.09*
低剂量组 0.082±0.015 0.41±0.06
中剂量组 0.075±0.012 0.39±0.06
高剂量组 0.086±0.015 0.46±0.12*
死菌低剂量组 0.080±0.015 0.39±0.08
死菌中剂量组 0.085±0.019 0.44±0.09*
死菌高剂量组 0.086±0.011 0.45±0.06*
注：*与对照组比较，差异具有显著性。
3.4检测指标
3.4.1小鼠结肠长度检测结果
小鼠结肠长度结果如表8所示，造模后，模型组小鼠结肠长度显著低于对照组(p ＜0.05)；样品干预后，各组小鼠结肠长度与模型组比较无显著性差异(p＞0.05)，说明本实验中对小鼠结肠长度其主要作用的为5％DSS，样品短期干预对小鼠结肠长度无显著影响。
表8小鼠结肠长度测量结果
组别 结肠长度(cm)
对照组 12.51±0.92
模型组 7.78±1.53*
低剂量组 7.81±1.10*
中剂量组 8.81±0.83*
高剂量组 8.15±1.47*
死菌低剂量组 8.40±1.09*
死菌中剂量组 7.96±1.69*
死菌高剂量组 7.64±1.09*
注：*与对照组比较，差异具有显著性3.4.2IL-6检测结果
3.4.2结肠IL-6检测结果
结肠IL-6变化结果如图1所示，与对照组比较，模型组小鼠结肠IL-6显著高于对照组(p＜0.05)，表明小鼠DSS干预可以起小鼠肠道炎症反应的增加，表现为炎性因子IL-6的增高。与模型组比较，BL-99中剂量组与死菌低剂量组小鼠结肠IL-6显著低于模型组(p＜0.05)；表明益生菌干预后，中、高剂量的BL-99及低剂量死菌可减少小鼠肠道炎症反应。
3.4.3结肠IL-10检测结果
结肠IL-10变化结果如图2所示，与对照组比较，模型组结肠IL-10虽上升，但差距没有显著性(p＞0.05)，表明造模具有导致肠道抗炎因子IL-10分泌增加的趋势。与模型组比较，中剂量组、高剂量组小鼠结肠IL-10均显著增高(p＜0.05)，表明益生菌干预后，中、高剂量BL-99具有促进肠道抗炎细胞产生抗炎因子IL-10的作用。
3.4.4结肠TNF-α检测结果
结肠IL-10变化结果如图3所示，与模型组比较，BL-99低、中、高剂量组、死菌高剂量组结肠TNF-α均有下降趋势，其中死菌低剂量组小鼠结肠TNF-α显著降低(p＜0.05)，说明益生菌中低剂量死菌可减少肠道炎症反应，减少结肠炎性因子TNF-α的分泌。
3.4.5病理学结果
3.4.5.1病理切片
病理学切片结果如图4所示，对照组小鼠的组织学观察可以看到完整的结肠上皮细胞，并可看到清晰的隐窝结构和杯状细胞。DSS诱导形成的模型组结肠炎小鼠的组织学观察，不能看到完整的结肠上皮细胞，同时出现隐窝不完全、杯状细胞损坏的现象，损坏面积均在50％以上，部分小鼠隐窝完全消失，杯状被完全破坏。另外还可以观察到小鼠炎性细胞浸润，如中性粒细胞和淋巴细胞等。小鼠经BL-99干预后DSS造模，出现了炎性细胞浸润、少部分隐窝消失，杯状细胞被破坏，其中中剂量组炎症反应较为严重，其病变范围较大在50～75％，低、高剂量组病变范围较为局限，大部分在0～25％范围内。经死菌干预后DSS造模，出现了炎性细胞浸润、隐窝消失面积较广，杯状细胞被破坏，病变范围较为严重，大部分在50％范围内。
3.4.5.2对小鼠组织学伤损评分分析
组织学损伤评分结果如图5所示，与模型组比较，各组结肠组织学伤损评分均具有下降趋势，其中BL-99低、高剂量组和死菌低、中、高剂量组组织学伤损评分均显著低于对模型组(p＜0.05)，说明以上各组益生菌对小鼠结肠损伤具有减轻小鼠结肠炎症症状的作用。
DSS诱导的结肠炎是实验性动物结肠炎模型最常见的方法，通常都是小鼠自由饮用7天左右即可形成实验性结肠炎模型。本试验采用5％DSS作为造模浓度，模型组为出现死亡，且小鼠在第3天开始出现便血情况，随时间延长，便血情况加重，便血只数增加，表明模型建立稳定性好。
BL-99各剂量组小鼠出现血便的时间较模型组晚，小鼠血便只数较模型组少，症状较轻，直接表明益生菌的抗炎症反应作用。而死菌干预组小鼠血便时间与模型组一致，血便出现情况较为频繁，这是因为益生菌经灭活后，其对肠道的调节作用降低，从而导致肠道炎症发生率较高。
IL-6为一种多功能的关键细胞因子，能够调节其他细胞因子的表达。在DSS诱导的实验性结肠炎的过程中，IL-6作为促炎因子，其表达水平的高低与结肠研中炎症程度的深浅有着密切的关系,缺乏IL-10的小鼠表现出严重的肠道炎症，且IL-10在动物结肠炎模型中表现良好的治疗效果,TNF-α是一种涉及到***性炎症的细胞因子。本研究中，模型组小鼠结肠IL-6显著升高，而BL-99中、高剂量组、死菌低剂量组小鼠结肠IL-6与模型组比较均较低，BL-99中、高剂量组小鼠结肠抗炎因子IL-10含 量增高，说明中、高剂量的BL-99促进了结肠炎中IL-10水平，增强抗炎作用说明BL-99及灭活益生菌均可减轻小鼠肠道炎症反应，缓解了DSS诱导的实验性结肠炎症状。
BL-99和灭活菌干预后小鼠在结肠组织损伤评分上与模型组有着明显的差异，具体表现在炎性细胞浸润程度较低、病变深度主要在粘膜下层，基底隐窝破坏较少，切片病变范围也较小，直观的显示BL-99活菌和死菌可以减轻DSS模型小鼠结肠炎症程度。
以上研究结果证实：乳双歧杆菌BL-99能显著抑制炎症因子IL-6和TNF-α，提升抑炎因子IL-10，恢复结肠组织损失的作用，可以用于食品，如发酵乳、乳酪、含乳饮料、乳粉或其它含有该菌株及其衍生物的任何一种食品。

Claims (10)

  1. 一种乳双歧杆菌(Bifidobacterium lactis)在制备用于抑制肠道炎症的组合物中的应用，所述乳双歧杆菌的保藏编号为CGMCC No.15650。
  2. 根据权利要求1所述的应用，其中，所述乳双歧杆菌以活菌和/或死菌的固态或液态菌制剂的形式用于制备所述组合物。
  3. 根据权利要求1所述的应用，其中，所述组合物包括食品组合物、饲料组合物或药品组合物。
  4. 根据权利要求1所述的应用，其中，所述组合物是用于降低炎症因子IL-6和/或TNF-α。
  5. 根据权利要求4所述的应用，其中，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天或0.01μg～100mg/天。
  6. 根据权利要求1所述的应用，其中，所述组合物是用于促进抑炎因子IL-10。
  7. 根据权利要求6所述的应用，其中，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天或0.01μg～100mg/天。
  8. 根据权利要求1所述的应用，其中，所述组合物是用于降低结肠炎组织损伤。
  9. 根据权利要求8所述的应用，其中，所述乳双歧杆菌的应用量为3.88×10 6CFU～3.88×10 13CFU/天或0.01μg～100mg/天。
  10. 根据权利要求4～9任一项所述的应用，其中，所述组合物为食品组合物，优选地，所述食品为发酵乳制品、乳酪、含乳饮料、固体饮料或乳粉。
PCT/CN2020/129990 2019-11-20 2020-11-19 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用 WO2021098755A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20889353.7A EP4070805A4 (en) 2019-11-20 2020-11-19 NEW USE OF BIFIDOBACTERIUM LACTIS BL-99 FOR INHIBITING INTESTINAL INFLAMMATION
JP2022529588A JP7492584B2 (ja) 2019-11-20 2020-11-19 ビフィドバクテリウム・ラクティスｂｌ－９９の腸管炎症の抑制における新規な用途
US17/778,587 US20220401499A1 (en) 2019-11-20 2020-11-19 New use of bifidobacterium lactis bl-99 in suppression of intestinal inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911139551.5A CN110893194B (zh) 2019-11-20 2019-11-20 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用
CN201911139551.5 2019-11-20

Publications (1)

Publication Number Publication Date
WO2021098755A1 true WO2021098755A1 (zh) 2021-05-27

Family

ID=69788257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/129990 WO2021098755A1 (zh) 2019-11-20 2020-11-19 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用

Country Status (5)

Country Link
US (1) US20220401499A1 (zh)
EP (1) EP4070805A4 (zh)
JP (1) JP7492584B2 (zh)
CN (1) CN110893194B (zh)
WO (1) WO2021098755A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110959676A (zh) * 2018-09-30 2020-04-07 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌的发酵乳制品及其应用
CN113736695A (zh) * 2021-08-24 2021-12-03 上海市第一人民医院 用于改善肠屏障功能的益生菌菌株及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110893194B (zh) * 2019-11-20 2023-03-14 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用
CN112870232A (zh) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用
CN114504106A (zh) * 2020-11-16 2022-05-17 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抗衰老、提高先天免疫方面的新应用
CN113736697B (zh) * 2021-09-01 2022-05-24 哈尔滨葵花药业有限公司 一株预防或治疗结肠炎的乳双歧杆菌及其应用
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140622A1 (en) * 2006-06-09 2007-12-13 Nutravital Inc. Dairy-derived probiotic compositions and uses thereof
CN102438637A (zh) * 2009-03-05 2012-05-02 益生菌股份公司 具有高抗炎活性的细菌菌株
CN110157650A (zh) * 2019-06-10 2019-08-23 北京科拓恒通生物技术股份有限公司 一株分离自母乳的乳双歧杆菌m8及其应用
CN110893194A (zh) * 2019-11-20 2020-03-20 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619748C (en) * 2005-08-30 2016-06-14 Actogenix Nv Novel treatment of chronic enterocolitis
CN102115721B (zh) * 2008-05-08 2012-09-26 景岳生物科技股份有限公司 具有抗炎活性的乳杆菌分离株及其用途
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
CA2938790A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
EP3194567B1 (en) * 2014-08-29 2019-10-30 Chr. Hansen A/S Probiotic bifidobacterium adolescentis strains
CN107723257A (zh) * 2017-09-20 2018-02-23 深圳市晨光乳业有限公司 一种动物双歧杆菌及其食品组合物
CN108486000B (zh) * 2018-03-12 2020-02-11 江南大学 一种双歧杆菌单菌发酵乳制备方法及其应用
CN110964657B (zh) * 2018-09-30 2021-03-12 内蒙古伊利实业集团股份有限公司 一种可提高免疫力的乳双歧杆菌bl-99及其应用
CN110964655B (zh) * 2018-09-30 2021-05-11 内蒙古伊利实业集团股份有限公司 一种乳双歧杆菌bl-99及其应用
IT201900016805A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
CN113736697B (zh) * 2021-09-01 2022-05-24 哈尔滨葵花药业有限公司 一株预防或治疗结肠炎的乳双歧杆菌及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140622A1 (en) * 2006-06-09 2007-12-13 Nutravital Inc. Dairy-derived probiotic compositions and uses thereof
CN102438637A (zh) * 2009-03-05 2012-05-02 益生菌股份公司 具有高抗炎活性的细菌菌株
CN110157650A (zh) * 2019-06-10 2019-08-23 北京科拓恒通生物技术股份有限公司 一株分离自母乳的乳双歧杆菌m8及其应用
CN110893194A (zh) * 2019-11-20 2020-03-20 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP4070805A4
YARD 1: "Beichen West Road", 26 April 2018, CHINESE ACADEMY OF SCIENCES

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110959676A (zh) * 2018-09-30 2020-04-07 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌的发酵乳制品及其应用
CN110959676B (zh) * 2018-09-30 2022-11-25 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌的发酵乳制品及其应用
CN113736695A (zh) * 2021-08-24 2021-12-03 上海市第一人民医院 用于改善肠屏障功能的益生菌菌株及其应用
CN113736695B (zh) * 2021-08-24 2023-02-03 上海市第一人民医院 用于改善肠屏障功能的益生菌菌株及其应用

Also Published As

Publication number Publication date
US20220401499A1 (en) 2022-12-22
CN110893194A (zh) 2020-03-20
EP4070805A4 (en) 2024-02-21
EP4070805A1 (en) 2022-10-12
JP7492584B2 (ja) 2024-05-29
JP2023502708A (ja) 2023-01-25
CN110893194B (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
WO2021098764A1 (zh) 副干酪乳杆菌k56在缓解肠道炎症方面的新应用
WO2021098755A1 (zh) 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用
CN110893195B (zh) 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
CN110964657B (zh) 一种可提高免疫力的乳双歧杆菌bl-99及其应用
US11268064B2 (en) Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases
CN113368139A (zh) 一种具有缓解肠易激综合征功效的微生物复合物及其制备方法和应用
CN110893193B (zh) 乳双歧杆菌bl-99的新应用
WO2020063553A1 (zh) 一种乳双歧杆菌bl-99及其应用
US11590180B2 (en) Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving allergic asthma
CN110643524B (zh) 一种具有胃肠道粘膜保护作用的复合益生菌制剂及其应用
US11376289B2 (en) Composition and uses thereof
CN111996153B (zh) 一种短双歧杆菌及其应用
CN110317761A (zh) 一种乳双歧杆菌及其应用
CN110882280A (zh) 副干酪乳杆菌k56的新应用
CN111826299A (zh) 一种润肠通便的动物双歧杆菌及其应用与制剂
KR101379404B1 (ko) 황금 발효물 및 이를 포함하는 항균 및 면역 증강 조성물
CN117100768A (zh) 嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)在改善和治疗腹泻中的应用
CN116121154A (zh) 一种乳明串珠菌及其应用
JP2008231094A (ja) 抗アレルギー剤
CN114686405B (zh) 一株具有减少脂肪和缓解高血糖，调节肠道免疫力的两歧双歧杆菌及其应用
WO2019227414A1 (zh) 一种组合物及其应用
CN116376740A (zh) 一株具有降血糖功效的长双歧杆菌及其应用
KR102579159B1 (ko) 신규한 사카로마이세스 보울라디 28-7 균주 및 이의 용도
CN117701477B (zh) 一株副干酪乳酪杆菌及其在改善肠道疾病中的应用
CN116617273A (zh) 副干酪乳杆菌lc86在制备用于预防、缓解或治疗与衰老相关的肌肉萎缩的产品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20889353

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022529588

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020889353

Country of ref document: EP

Effective date: 20220620